KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Development and pilot testing of AYA-RISE, a risk information and screening education intervention for adolescents and young adults with cancer risk syndromes. PMID 41575674 · Fam Cancer · 2026-Jan-23 The record describes a pilot study for a non-drug educational intervention, with no randomized trial results, no drug intervention, and no time-to-event endpoint reported.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel-Lindau disease to advanced renal cell carcinoma. PMID 41569310 · Cancer Chemother Pharmacol · 2026-Jan-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Ferric citrate for iron deficiency anemia in non-dialysis dependent chronic kidney disease: a randomized phase III study. PMID 41558722 · Kidney Res Clin Pract · 2026-Jan-21 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Correction: Wang et al. Immune Persistence Following a Single Dose of Varicella Vaccine: 5-Year and 8-Year Follow-Up of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Vaccines 2025, 13, 1024. PMID 41601025 · Vaccines (Basel) · 2026-Jan-20 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Menin Inhibition in Acute Myeloid Leukemia: Pathobiology, Progress and Promise. PMID 41595753 · Biomedicines · 2026-Jan-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-acting HIV pre-exposure prophylaxis integrated with community-based sexual and reproductive health services in South Africa (LAPIS): study protocol for a hybrid (1a) cluster randomised controlled phase 3B trial of effectiveness and implementation. PMID 41559582 · BMC Public Health · 2026-Jan-20 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Ligelizumab in Individuals With Confirmed Peanut Allergy. PMID 41555809 · Allergy · 2026-Jan-20 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Advances in the Diagnosis and Management of High-Risk Cardiovascular Conditions: Biomarkers, Intracoronary Imaging, Artificial Intelligence, and Novel Anticoagulants. PMID 41590879 · J Cardiovasc Dev Dis · 2026-Jan-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
30 years of thrombolysis for ischaemic stroke: expanded agents, widened windows and accelerated delivery. PMID 41554632 · Stroke Vasc Neurol · 2026-Jan-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis. PMID 41549666 · J Antimicrob Chemother · 2026-Jan-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option? PMID 41590374 · Curr Oncol · 2026-Jan-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Association between COVID-19 vaccine efficacy and epidemic force of infection. PMID 41547989 · NPJ Vaccines · 2026-Jan-17 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunotherapy rechallenge in metastatic renal cell carcinoma: a meta-analysis of randomized clinical trials. PMID 41452751 · Oncologist · 2026-Jan-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
MR GENTLE-multicentre randomised controlled trial of ghrelin in anterior circulation ischaemic stroke treated with endovascular thrombectomy: a phase 2 trial. PMID 41546024 · Trials · 2026-Jan-16 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of nurse navigation and mobile app on brain tumor patients receiving oral anticancer therapy. PMID 41540229 · NPJ Digit Med · 2026-Jan-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Quality of Life Measures in Advanced Endometrial Cancer: A Systematic Review of Reporting Practices in Phase III Clinical Trials. PMID 41595177 · Cancers (Basel) · 2026-Jan-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
An App-Based Behavioral Support Intervention Promoting Physical Activity (APPROACH) in Patients Diagnosed With Breast, Prostate, or Colorectal Cancer: Protocol for a Randomized Controlled Trial. PMID 41529252 · JMIR Res Protoc · 2026-Jan-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of adjuvant capecitabine and pembrolizumab in early-stage triple-negative breast cancer after standard neo-/adjuvant chemotherapy: A meta-analysis of phase III studies. PMID 41529117 · J Oncol Pharm Pract · 2026-Jan-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial. PMID 41526043 · BMJ · 2026-Jan-12 Title explicitly establishes a Phase III, randomized, drug-intervention trial with a survival endpoint in human oncology. However, the abstract is missing, so time-to-event (KM/HR) and human status cannot be definitively verified from the provided metadata. Therefore, eligibility is set to null.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Telehealth-delivered exercise and nutrition intervention to improve outcomes in patients with early stage non-small cell lung cancer: protocol for the multicentre STARLighT phase II (neoadjuvant) and phase III (adjuvant) trial. PMID 41526018 · BMJ Open · 2026-Jan-12 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of fixed-dose dapagliflozin-pioglitazone in Indian adults with type 2 diabetes: a phase 3 PRO-1 trial. PMID 41521288 · Diabetol Metab Syndr · 2026-Jan-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma. PMID 41329901 · J Clin Oncol · 2026-Jan-10 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 6 Figure · 6 Panel · risk visible
Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss. PMID 41598480 · J Clin Med · 2026-Jan-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Protocol summary of a randomized controlled phase III trial for confirming the superiority of local radiotherapy for prostate cancer patients with high-volume metastasis sensitive to hormonal therapy: the JCOG2011 (HimeRT study). PMID 41052091 · Jpn J Clin Oncol · 2026-Jan-09 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Protocol for a phase 2, partially blinded, randomized trial assessing the safety and efficacy of sorfequiline or bedaquiline in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis (NC-009). PMID 41495827 · Trials · 2026-Jan-06 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD. PMID 41436034 · Eur J Endocrinol · 2026-Jan-06 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-24. PMID 41400870 · J Antimicrob Chemother · 2026-Jan-06 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Prevention of postoperative complications with negative pressure wound therapy after complex breast cancer surgery: a study protocol of a randomised controlled trial (TPN-SEIN). PMID 41485781 · BMJ Open · 2026-Jan-03 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A Randomized Clinical Trial of Kidney Autologous Cell Therapy in Diabetic Kidney Disease. PMID 41481370 · Clin J Am Soc Nephrol · 2026-Jan-02 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
B-STARS2: Early contralesional continuous theta burst stimulation (cTBS) to promote upper limb recovery after stroke - Rationale and design of a phase-3 multicentre, randomised, sham-controlled, clinical trial. PMID 41614522 · Eur Stroke J · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Citicoline Triggers Proteome Remodeling and Proteostatic Adaptation: Evidence from Shotgun Proteomics. PMID 41599168 · Pharmaceutics · 2026-Jan-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis. PMID 41264309 · JAMA Oncol · 2026-Jan-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Novel niclosamide stearate prodrug therapeutic shows potential efficacy against naturally occurring canine osteosarcoma in a clinical feasibility study. PMID 41145069 · Am J Vet Res · 2026-Jan-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer. PMID 42395839 · Endocr Oncol · 2026-Jan The record describes a Phase III randomized controlled trial in oncology with a drug intervention and original results, but the primary endpoint is a change in biomarkers associated with metabolic syndrome, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP). No Kaplan-Meier survival curves or hazard ratios are reported or implied.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Reporting quality and risk of bias in randomized controlled trials of rotavirus vaccines. PMID 41660219 · Clin Exp Vaccine Res · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Overview of the Efficacy and Safety of Topical Hormonal Therapies for the Treatment of Acne Vulgaris: A Narrative Review. PMID 41648090 · J Clin Aesthet Dermatol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Mirvetuximab soravtansine-Gynx (MIRV) for treating platinum-resistant recurrent ovarian cancer. PMID 41617329 · Taiwan J Obstet Gynecol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Time-Dependent Comparative Effectiveness of First-Line Treatment for Metastatic Clear Cell Renal Cell Carcinoma: A Restricted Mean Survival Time-Based Network Meta-analysis. PMID 41575641 · Target Oncol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
An Improved Bayesian Pick-the-Winner (IBPW) Design for Randomized Phase II Clinical Trials. PMID 41569686 · Stat Med · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Diagnostic and Therapeutic Potential of Substance P/NK1 Receptor in Primary Dysmenorrhea: A Pilot Study. PMID 41561887 · Health Sci Rep · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Real-world effectiveness of biologic therapies in severe asthma patients ineligible for phase 3 randomised controlled trials of biologics: an analysis from the UK Severe Asthma Registry. PMID 41561108 · ERJ Open Res · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Triplet regimens for frontline treatment of CLL-Great company or just a crowd? PMID 41560849 · Hemasphere · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The evolving role of radiotherapy in advanced non-small cell lung cancer: beyond symptom control. PMID 41560507 · Ann Palliat Med · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Learning together to promote mental health and well-being in English secondary schools: LTMH study refinement and feasibility evaluation, a comprehensive synopsis. PMID 41556286 · Public Health Res (Southampt) · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Iptacopan in Patients With IgA Nephropathy From East Asia. PMID 41541777 · Kidney Int Rep · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A randomized phase III trial of structured tumour response surveillance and shared decision-making for organ preservation in rectal cancer - PRODIGE 101-GRECCAR 20-EVAREC trial protocol. PMID 41536139 · Colorectal Dis · 2026-Jan 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Association Between the Angioedema Control Test and Attack Frequency in Hereditary Angioedema. PMID 41525239 · Clin Transl Allergy · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The effects of discriminative stimuli on combined relapse: A preliminary human-operant investigation. PMID 41508914 · J Exp Anal Behav · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase III Study Investigating the Safety and Efficacy of TM5614 in Combination With Nivolumab for the Treatment of Unresectable Malignant Melanoma: Protocol. PMID 41504650 · Exp Dermatol · 2026-Jan 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Validation of PREDICT tool v2.2 in patients with early-stage breast cancer enrolled in the GIM and MIG trials. PMID 41499989 · ESMO Open · 2026-Jan The record analyzes data from Phase III randomized oncology trials and uses a time-to-event endpoint (OS). However, it is a secondary validation study of a prognostic tool (PREDICT v2.2) using pooled trial data, not an original report of a randomized trial comparing a drug-containing intervention. The abstract does not specify any drug interventions being evaluated in the trials; it only mentions analyzing existing trial data for prognostic validation purposes. Therefore, it fails the drug intervention and original result criteria.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -